Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer

Basit Öğe Kaydı
dc.contributor.authorTuran, Nedim
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorDane, Faysal
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorKara, Hasan Volkan
dc.contributor.authorKoca, Dogan
dc.contributor.authorBalvan, Ozlem
dc.date.accessioned2024-02-23T14:24:00Z
dc.date.available2024-02-23T14:24:00Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractIntroduction: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC). Methods: A total of 122 consecutive patients who were curatively resected for pulmonary metastases of CRC in twelve oncology centers were retrospectively analysed between January 2000 and April 2012. Results: Of 122 patients, 14 did not receive any treatment following PM. The remaining 108 patients received fluoropyrimidine-based (n = 12), irinotecan-based (n = 56) and oxaliplatin-based (n = 40) chemotherapy combinations. Among these, 52 patients received bevacizumab (BEV) while 56 did not (NoBEV). Median recurrence-free survival (RFS) was 17 months and median overall survival (OS) has not been reached at amedian follow-up of 25 months after PM. Three and five-year OS rates were 66% and 53%, respectively. RFS and OS were similar, irrespective of the chemotherapy regimen or BEVuse. Positive pulmonary margin, KRASmutation status, and previous liver metastasectomy were negative independent prognostic factors for RFS, while pathologically confirmed thoracic lymph node involvement was the only negative independent prognostic for OS in multivariate analysis. Conclusions: No significant RFS or OS difference was observed in respect to chemotherapy regimens with or without BEV in patients with pulmonary metastases of CRC following curative resection.en_US
dc.identifier.doi10.1111/1759-7714.12107
dc.identifier.endpage404en_US
dc.identifier.issn1759-7706
dc.identifier.issn1759-7714
dc.identifier.issue5en_US
dc.identifier.pmid26763794en_US
dc.identifier.scopus2-s2.0-84906493835en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage398en_US
dc.identifier.urihttps://doi.org/10.1111/1759-7714.12107
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13767
dc.identifier.volume5en_US
dc.identifier.wosWOS:000341239500005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofThoracic Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectBevacizumaben_US
dc.subjectColorectal Canceren_US
dc.subjectPulmonary Metastasectomyen_US
dc.titleAdjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu